Xtant Medical Holdings

Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoSTX, Certex Spinal Fixation System, Axle Interspinous Fusion System, and Calix. Thecompany was founded in 2006 and is headquartered in Belgrade, MT.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoSTX, Certex Spinal Fixation System, Axle Interspinous Fusion System, and Calix. The company was founded in 2006 and is headquartered in Belgrade, MT.

Xtant Medical Holdings Inc. (XTNT) Q4 2023 Earnings Call Transcript

Establishes Full Year 2024 Revenue Guidance of $112 Million - $116 Million BELGRADE, Mont., April 01, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2023.

Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 Million

BELGRADE, Mont., March 21, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2023, before the open of the financial markets on Monday, April 1, 2024.

Xtant Medical to Issue Fourth Quarter and Full Year 2023 Financial Results on April 1, 2024

BELGRADE, Mont., March 07, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that the Company's revolving credit agreement with MidCap Financial Trust (“MidCap”) was amended to increase the commitment from $8.0 million to $17.0 million. The Company's term loan was also amended to provide for an additional $10.0 million tranche, to be made available for acquisitions at MidCap's discretion. The maturity dates of Xtant's revolving credit facility and term loan were extended to March 1, 2029 and minimum net product revenue requirements specified in the agreements were reset and minimum Adjusted EBITDA requirements were removed. Additionally, the applicable margin used to determine the per annum interest rate of the term loan was reduced from 7.00% to 6.50%.

Xtant Medical Increases Revolving Credit Facility to $17 Million with MidCap Financial

BELGRADE, Mont., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that Sean Browne, Chief Executive Officer, will present at the TD Cowen 44th Annual Healthcare Conference, to be held on Monday, March 4, 2024 at 12:50 p.m. Eastern Time in Boston.

Xtant Medical to Present at the TD Cowen 44th Annual Healthcare Conference

BELGRADE, Mont., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that management will participate in two upcoming investor conferences:

Xtant Medical to Participate in Upcoming Investor Conferences

BELGRADE, Mont., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2023.

Xtant Medical Announces Record Third Quarter Revenue of $25 Million

Expands Xtant's Manufacturing Capabilities and Capacity to Drive Growth BELGRADE, Mont., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has acquired the nanOss production operations from RTI Surgical, Inc., a leading CDMO in regenerative medicine.

Xtant Medical Announces Acquisition of nanOss Production Operations from RTI Surgical

BELGRADE, Mont., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it will exhibit its suite of orthobiologics and spinal fixation products at the North American Spine Society (NASS) 2023 Annual Meeting, which will be held October 18-21 at the Los Angeles Convention Center in Los Angeles, CA.

Xtant Medical Highlights Growing Product Portfolio at NASS 2023

BELGRADE, Mont., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it completed the acquisition of certain assets and liabilities related to the domestic and international biologics and spinal fixation offerings of Surgalign Holdings, Inc. under a Bankruptcy Court supervised process for $5 million, plus assumed liabilities, in an all-cash transaction.

Xtant Medical Completes Acquisition of Surgalign's Hardware and Biologics Business

Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q2 2023 Earnings Conference Call August 1, 2023 9:00 AM ET Company Participants Matt Steinberg - IR Sean Browne - CEO Scott Neils - CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings. You're welcome Xtant Medical's Second Quarter 2023 Financial Results Conference Call.

Xtant Medical Holdings, Inc. (XTNT) Q2 2023 Earnings Call Transcript

Raises 2023 Annual Revenue Guidance to $75 Million - $77 Million BELGRADE, Mont., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2023.

Xtant Medical Announces Second Quarter Revenue Growth of 32%

Acquisition to Enhance Xtant's Growing Spinal Fusion Devices Portfolio BELGRADE, Mont., July 28, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it was the successful bidder for certain assets and liabilities related to the domestic and international biologics and spinal fixation offerings of Surgalign Holdings, Inc. Xtant's initial bid, as set forth in the Asset Purchase Agreement, dated June 18, 2023, between Xtant and Surgalign, was the winning bid.

Xtant Medical Wins Auction for Surgalign's Hardware and Biologics Business

BELGRADE, Mont., July 25, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the second quarter ended June 30, 2023, before the open of the financial markets on Tuesday, August 1, 2023.

Xtant Medical to Issue Second Quarter 2023 Financial Results on August 1, 2023

BELGRADE, Mont., July 07, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the closing of its previously announced $15 million private placement with accredited investors. The Company sold 20 million shares of common stock at a purchase price of $0.75 per share. After deducting fees and other estimated offering expenses, the Company received net proceeds of approximately $14.2 million.

Xtant Medical Announces Closing of $15 Million Private Placement

BELGRADE, Mont., July 03, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has entered into a securities purchase agreement with accredited investors to sell shares of its common stock in a private placement. The Company agreed to issue an aggregate of 20,000,000 shares of common stock at a purchase price of $0.75 per share, resulting in gross proceeds of $15 million.

Xtant Medical Announces $15 Million Private Placement

BELGRADE, Mont., May 18, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Lori Mitchell-Keller to the Company's Board of Directors effective May 16, 2023. Ms. Mitchell-Keller will serve as a member of the Compensation and Audit Committees of the Board of Directors.

Xtant Medical Appoints Lori Mitchell-Keller to Board of Directors

Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q1 2023 Earnings Conference Call May 4, 2023 9:00 AM ET Company Participants Matt Steinberg - IR Sean Browne - CEO Scott Neils - CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Kyle Rose - Canaccord Genuity Operator Greetings. You're welcome Xtant Medical's Q1 2023 financial results call.

Xtant Medical Holdings, Inc. (XTNT) Q1 2023 Earnings Call Transcript

Initiates Annual Revenue Guidance of $73 Million - $75 Million in Full Year 2023 BELGRADE, Mont., May 04, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2023.

Xtant Medical Announces First Quarter 2023 Revenue Growth of 38% and Full Year 2023 Revenue Guidance

Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q4 2022 Earnings Conference Call March 7, 2023 9:00 AM ET Company Participants Matt Steinberg - IR, FINN Partners Sean Browne - President and Chief Executive Officer Scott Niels - Chief Financial Officer Conference Call Participants Operator Greetings and welcome to the Xtant Medical Fourth Quarter and Full Year 2022 Financial Results Conference Call [Operator Instructions]. As a reminder, this conference is being recorded.

Xtant Medical Holdings, Inc. (XTNT) Q4 2022 Earnings Call Transcript

BELGRADE, Mont., March 07, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2022.

Xtant Medical Announces Fourth Quarter and Full Year 2022 Financial Results

BELGRADE, Mont., March 03, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2022, before the open of the financial markets on Tuesday, March 7, 2023.

Xtant Medical to Issue Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023

BELGRADE, Mont., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that Sean Browne, Chief Executive Officer, will present at the Canaccord Musculoskeletal Conference, to be held on Tuesday, March 7, 2023 at 3:30 p.m. Pacific Time in Las Vegas.

Xtant Medical to Present at the Canaccord Musculoskeletal Conference on March 7, 2023

Company Sponsors Donate Life Float at Rose Parade for the Ninth Year

Xtant Medical Honors Donor Hero Asante Contreras on the Donate Life Rose Parade® Float

Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q3 2022 Results Conference Call November 3, 2022 9:00 AM ET Company Participants Matt Steinberg - IR, FINN Partners Sean Browne - President and Chief Executive Officer Scott Niels - Chief Financial Officer Operator Greetings, and welcome to the Xtant Medical Q3 2022 Financial Results Conference Call [Operator Instructions]. As a reminder, this conference is being recorded.

News for Xtant Medical Holdings Stock (XTNT)